Burning Rock
360Dx Top 30 Ticks Down in August
Out of the 30 companies in the index, 21 firms saw their stock prices decrease, while nine saw their share prices go up.
Burning Rock Biotech Q2 Revenues up 12 Percent
The company is continuing to shift its focus to marketing in-hospital test kits with a resulting shrinkage of its central laboratory test volume and revenue.
360Dx Top 30 Rebounds in June, Rising 4 Percent
Of the 30 companies in the Top 30, 20 saw their stock prices go up, while 10 saw their share prices decline.
Burning Rock Biotech Q1 Revenues up 5 Percent
The company saw continued shrinkage in its central laboratory business due to the COVID-19 pandemic in January coupled with significant growth in pharma services.
360Dx Top 30 Slides 2 Percent in April
Of the 30 companies in the index, 19 saw their share prices decrease, while 11 saw their stock prices rise.
Nov 16, 2022
Burning Rock Biotech Q3 Revenues Climb 22 Percent
Sep 1, 2022
360Dx Top 30 Tumbles in August
Jul 1, 2022
360Dx Top 30 Drops 5 Percent in June
May 31, 2022
Burning Rock Biotech Q1 Revenues up 27 Percent
Apr 1, 2022
360Dx Top 30 Falls Slightly in March
Mar 22, 2022
Burning Rock Q4 Revenues up 12 Percent
Jan 4, 2022